Read by QxMD icon Read

metoclopramide AND CINV

Deepti Ahuja, Sachidanand J Bharati, Nishkarsh Gupta, Ritesh Kumar, Sushma Bhatnagar
Radiation-induced nausea and vomiting (RINV) is one of the most distressing symptoms that adversely affects quality of life (QOL) as well as the ongoing management plan of cancer patients. Although there are protocols for management of chemotherapy induced nausea and vomiting (CINV) but such guidelines are still lacking for RINV. Various agents like 5-hydroxy tryptophan 3 (5-HT3) antagonist, dexamethasone, metoclopramide and haloperidol are used in clinical practice for RINV but the results are not very encouraging...
August 23, 2016: Annals of Palliative Medicine
Fateme Sanaati, Safa Najafi, Zahra Kashaninia, Masoud Sadeghi
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) places a significant burden on the patient. Herbal agents are the most commonly complementary therapies used among the public. This study was done to determine the effect of ginger and chamomile capsules on nausea and vomiting in cases undergoing chemotherapy for breast cancer (BC). MATERIALS AND METHODS: In a randomized, double-blind and clinical trial study, 65 women with BC undergoing chemotherapy were referred to Breast Cancer Research Center, Tehran, Iran, between May 2013 to June 2014...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
Snezana M Bosnjak, Jelena Dimitrijevic, Fedja Djordjevic
PURPOSE OF THE REVIEW: The purpose of review is to critically present the evidence supporting the use of olanzapine, an atypical antipsychotic, as an antiemetic for cancer and chemotherapy-induced nausea and vomiting (CINV). RECENT FINDINGS: Two phase III clinical studies demonstrated superior efficacy of olanzapine in comparison with the neurokinin-1 receptor antagonists (NK1RA) for substance P (aprepitant, fosaprepitant) in the prevention of nausea after highly emetogenic chemotherapy...
June 2016: Current Opinion in Supportive and Palliative Care
Melissa Lau Moon Lin, Paula D Robinson, Jacqueline Flank, Lillian Sung, L Lee Dupuis
INTRODUCTION: Metoclopramide is recommended for adults with breakthrough or refractory chemotherapy-induced nausea and vomiting (CINV) and for CINV prophylaxis in children. The drug regulatory agencies of Canada and the EU have revised the labelling of metoclopramide to contraindicate its use in children aged <1 year and to caution against its use in children aged <5 years and its duration of use beyond 5 days. OBJECTIVE: This review describes the safety of metoclopramide in children when given for any indication...
July 2016: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
Mellar P Davis
A number of new advances have occurred over the past 2 years in the management of chemotherapy-related nausea and vomiting (CINV). A new neurokinin-1 receptor antagonist (NK1RA), netupitant, has been combined with palonosetron in a single oral tablet for treating the effects of moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC). Rolapitant, another NK1RA, unlike aprepitant, has a long half-life and does not block CYP-3A4 and therefore has fewer drug interactions. Olanzapine reduces nausea more effectively than aprepitant in patients who are receiving HEC and is a better rescue antiemetic than is metoclopramide...
January 2016: Journal of Community and Supportive Oncology
Kazem Anvari, Mehdi Seilanian-Toussi, Hossein Hosseinzad-Ashkiki, Soodabeh Shahidsales
BACKGROUND: Chemotherapy- induced nausea and vomiting (CINV) occur frequently causing problems with an unacceptably high incidence that significantly affect patients' daily functioning and health-related quality of life. The present study was aimed to compare acute CINV for granisetron as 5-HT3 receptor antagonist and metoclopramide in the patients receiving chemotherapeutic regimens including cyclophosphamide and adriamycin. An attempt is made to examine whether it is possible to successfully replace granisetron with metoclopramide in control of acute CINV...
March 2015: Iranian Journal of Cancer Prevention
Megan V Brafford, Ashley Glode
Despite the appropriate use of pharmacologic and nonpharmacologic preventative measures, chemotherapy-induced nausea and vomiting (CINV) can be debilitating and can decrease quality of life for many patients. In addition, patients may be unwilling to continue chemotherapy treatment due to the uncontrollable nausea and vomiting associated with their therapy. Refractory CINV can occur at any point in a treatment cycle, despite adequate therapy for acute and delayed CINV. Current prevention strategies include using serotonin (5-HT3) receptor antagonists, corticosteroids, and/or neurokinin-1 receptor antagonists...
January 2014: Journal of the Advanced Practitioner in Oncology
Weiheng Hu, Jian Fang, Jun Nie, Ling Dai, Xiaoling Chen, Jie Zhang, Xiangjuan Ma, Guangming Tian, Jindi Han
OBJECTIVE: We investigated whether aprepitant, a neurokinin-1 antagonist, could decrease chemotherapy-induced nausea and vomiting (CINV) following cisplatin, when a conventional anti-emetic regimen had failed. METHODS: This was a prospective study (April 2011-April 2012) of patients with lung cancer, treated with cisplatin at the Beijing Cancer Hospital, and initially receiving granisetron, dexamethasone, and metoclopramide as anti-emetics. If patients experienced vomiting of grade ≥2 and required rescue anti-emetic medications during the first cycle, oral aprepitant was added in subsequent cycles (day 1: 125 mg; days 2-3: 80 mg once daily)...
June 2014: Cancer Chemotherapy and Pharmacology
Chan Huan Keat, Norazila Abdul Ghani
BACKGROUND: In a prospective cohort study of antiemetic therapy conducted in Malaysia, a total of 94 patients received low emetogenic chemotherapy (LEC) with or without granisetron injections as the primary prophylaxis for chemotherapy-induced nausea and vomiting (CINV). This study is a retrospective cost analysis of two antiemetic regimens from the payer perspective. MATERIALS AND METHODS: This cost evaluation refers to 2011, the year in which the observation was conducted...
2013: Asian Pacific Journal of Cancer Prevention: APJCP
Samantha Humphreys, James Pellissier, Alison Jones
PURPOSE: Prevention of chemotherapy-induced nausea and vomiting (CINV) remains an important goal for patients receiving chemotherapy. The objective of this study was to define, from the UK payer perspective, the cost-effectiveness of an antiemetic regimen using aprepitant, a selective neurokinin-1 receptor antagonist, for patients receiving chemotherapy for breast cancer. METHODS: A decision-analytic model was developed to compare an aprepitant regimen (aprepitant, ondansetron, and dexamethasone) with a standard UK antiemetic regimen (ondansetron, dexamethasone, and metoclopramide) for expected costs and health outcomes after single-day adjuvant chemotherapy for breast cancer...
2013: Cancer Management and Research
Jiyeon Lee, Heeyoung Oh
PURPOSE/OBJECTIVES: To evaluate the effect of ginger as an antiemetic modality for the control of chemotherapy-induced nausea and vomiting (CINV). DATA SOURCES: Databases searched included MEDLINE® (PubMed), Embase, CINAHL®, Cochrane Central Register of Controlled Trials, Korean Studies Information Service System, Research Information Sharing Service by the Korean Education and Research Information Service, and Dissertation Central. DATA SYNTHESIS: A systematic review was conducted of five randomized, controlled trials involving 872 patients with cancer...
March 2013: Oncology Nursing Forum
Rudolph M Navari, Cindy K Nagy, Sarah E Gray
PURPOSE: Olanzapine has been shown to be a safe and effective agent for the prevention of chemotherapy-induced nausea and vomiting (CINV). Olanzapine may also be an effective rescue medication for patients who develop breakthrough CINV despite having received guideline-directed CINV prophylaxis. METHODS: A double-blind, randomized phase III trial was performed for the treatment of breakthrough CINV in chemotherapy-naive patients receiving highly emetogenic chemotherapy (cisplatin, ≥ 70 mg/m2 or doxorubicin, ≥ 50 mg/m2 and cyclophosphamide, ≥ 600 mg/m2), comparing olanzapine to metoclopramide...
June 2013: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
E Oddby-Muhrbeck, E Öbrink, S Eksborg, S Rotstein, P A Lönnqvist
BACKGROUND: Drug-induced nausea and vomiting, both post-operatively and following chemotherapy, is often distressing for the patients. Our clinical impression is that certain patients are not prone to but instead protected against both post-operative and chemotherapy-induced nausea and vomiting (CINV). If support for this hypothesis could be generated, it might be easier to identify such patients as low-risk patients and judge all other patients as high-risk patients by default. METHODS: All patients scheduled for breast cancer surgery at Danderyd Hospital, Stockholm, Sweden during 1 year (March 2003-March 2004) were asked to participate in this prospective, observational study...
July 2013: Acta Anaesthesiologica Scandinavica
Alexandre Chan, Xiu Hui Low, Kevin Yi-Lwern Yap
BACKGROUND: There are little prevalence data in the literature on nonadherence to outpatient antiemetic regimens for prophylaxis of chemotherapy-induced nausea and vomiting (CINV). It is unclear whether adherence with outpatient antiemetic regimens is associated with better CINV control. Our previous survey research supports the work of clinical pharmacists in collaborative practice with medical oncologists in improving adherence with antiemetic therapy in women undergoing highly emetic chemotherapy for breast cancer...
June 2012: Journal of Managed Care Pharmacy: JMCP
Rita Wickham
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) is one of the most debilitating toxicities associated with cancer treatment. Although effective antiemetic agents are available, their use in practice often is suboptimal. METHODS: The author reviews the pathophysiology of CINV as well as the drug classes and cost considerations that should be incorporated into treatment planning. RESULTS: Several drug classes, including 5-hydroxytryptamine-3 receptor antagonists, neurokinin-1 receptor antagonists, and corticosteroids, are effective, especially when used in combination...
April 2012: Cancer Control: Journal of the Moffitt Cancer Center
Jung Hun Kang, David Hui, Moon Jin Kim, Hoon Gu Kim, Myoung Hee Kang, Gyeong-Won Lee, Eduardo Bruera
Dexamethasone, one of the key medications for the prevention of chemotherapy-induced nausea and vomiting (CINV), may cause hiccups as an adverse effect. In this case series, we present five patients who developed hiccups after receiving dexamethasone for CINV. We successfully switched dexamethasone to an equipotent dosage of either methylprednisolone or prednisolone, which resolved the hiccups while maintaining adequate control of CINV. This was achieved without changing the rest of the antiemetic regimen, chemotherapy doses, or the use of other medications such as baclofen, haloperidol, and metoclopramide for hiccups...
March 2012: Journal of Pain and Symptom Management
Karin Jordan, Fausto Roila, Alexander Molassiotis, Ernesto Maranzano, Rebecca A Clark-Snow, Petra Feyer et al.
Only a few studies have been carried out in children on the prevention of chemotherapy-induced nausea and vomiting (CINV). 5-HT(3) receptor antagonists have been shown to be more efficacious and less toxic than metoclopramide, phenothiazines and cannabinoids. Most dose studies are available for the 5-HT(3) receptor antagonists ondansetron and granisetron. The new 5-HT(3) receptor antagonist palonosetron was evaluated in one comparative study so far showing promising activity. Combinations of a 5-HT(3) receptor antagonist and dexamethasone showed increased efficacy with respect to a 5-HT(3) receptor antagonist alone...
March 2011: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Béla Pikó, Ali Bassam
Even today, nausea and vomiting are two of the most distressing adverse effects associated with tumor therapy. The authors give an overview of the mechanism and the trigger factors (emetogenic potential of the chemotherapies, the patient risk factors, and the used antiemetic drugs) of nausea and vomiting. A short summary will describe the antiemetic drugs focusing on metoclopramide, steroid and the currently widely used setron therapy which is effective only during the acute phase of chemotherapy-induced nausea and vomiting (CINV)...
March 2009: Magyar Onkologia
Rebecca Hawkins, Steven Grunberg
Oncology nurses play a pivotal role in the care of patients receiving chemotherapy and are in a prime position to facilitate better care of patients experiencing chemotherapy-induced nausea and vomiting (CINV). However, to do so, they must be kept well apprised of the most recent guidelines, the latest developments in CINV therapy, and the expanding knowledge of CINV pathophysiology. In April 2008, a roundtable meeting of experts in the field of CINV was convened after a detailed needs assessment revealed a knowledge gap in CINV management on the part of oncology nurses...
February 2009: Clinical Journal of Oncology Nursing
Maurizio Musso, Renato Scalone, Vincenza Bonanno, Alessandra Crescimanno, Vita Polizzi, Ferdinando Porretto, Carlo Bianchini, Tania Perrone
OBJECTIVE: The objective of this study was to determine the efficacy of palonosetron combined with dexamethasone in prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving multiple-day chemotherapy and the efficacy of a second dose of palonosetron in treating breakthrough emesis. MATERIALS AND METHODS: Forty-six patients treated with multiple-day chemotherapy for hematologic malignancies received palonosetron as prophylaxis for CINV on the first day of chemotherapy and dexamethasone throughout the entire period of chemotherapy...
February 2009: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"